United States — Food and Drug Administration & AbbVie
8 shared events · Importance 6 · Last updated Jul 29, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.
AbbVie: AbbVie is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Business
United States — Food and Drug Administration: The Taiwan FDA granted marketing approval for QUVIVIQ, a regulatory milestone that enables commercialization in Taiwan.
AbbVie: AbbVie achieved third and fourth research milestones under its collaboration with Nxera, resulting in US$20 million in milestone payments to Nxera. This reflects progress in neurological disease programs.
Aug 07, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA classified the recall as Class II and issued public notices, reinforcing its regulatory oversight role.
AbbVie: AbbVie now owns the brand Pred Forte, but is not directly affected by the recall of the generic version.
Jul 07, 2026 · 38 articles
Business
United States — Food and Drug Administration: Piramal Group completed three USFDA inspections with zero OAI observations, reflecting strong quality standards.
AbbVie: AbbVie is a joint venture partner in Abbvie Therapeutics India Private Limited, mentioned as an associate company.
Jul 07, 2026 · 14 articles
Business
United States — Food and Drug Administration: The FDA approved Palsonify in 2025, enabling its commercial availability. The agency's regulatory decisions are relevant to the value of the acquired assets.
AbbVie: Mentioned as part of 2026 M&A activity; acquired Apogee for $10.9B.
Jul 06, 2026 · 34 articles
Business
United States — Food and Drug Administration: The FDA granted Breakthrough Therapy Designation to BPL-003 and announced regulatory actions to support psychedelic drug development, facilitating the path to market.
AbbVie: AbbVie is a competitor that previously acquired KC Pharmaceuticals for up to $1.2B in 2024, highlighting industry interest in psychedelic therapies.
Jul 16, 2026 · 25 articles
Business
United States — Food and Drug Administration: The US FDA issued an Establishment Inspection Report to Piramal Group's Sellersville facility, confirming quality compliance.
AbbVie: AbbVie is a joint venture partner in Abbvie Therapeutics India Private Limited, mentioned as an associate company.
Jul 29, 2026 · 10 articles
Tech
AbbVie: AbbVie Inc. is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and AbbVie interact across events, view sentiment trends, and discover connected entities.
Open Dashboard